Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
2.160
0.00 (0.00%)
Jun 30, 2026, 10:49 AM EDT - Market open
Compugen Employees
Compugen had 75 employees as of December 31, 2025. The number of employees increased by 1 or 1.35% compared to the previous year.
Employees
75
Change (1Y)
1
Growth (1Y)
1.35%
Revenue / Employee
$968,747
Profits / Employee
$464,733
Market Cap
204.30M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75 | 1 | 1.35% |
| Dec 31, 2024 | 74 | 6 | 8.82% |
| Dec 31, 2023 | 68 | -1 | -1.45% |
| Dec 31, 2022 | 69 | -4 | -5.48% |
| Dec 31, 2021 | 73 | 5 | 7.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| MediWound | 121 |
| Arcturus Therapeutics Holdings | 111 |
| Nkarta | 108 |
| NovaBridge Biosciences | 30 |
| Unicycive Therapeutics | 22 |
| Equillium | 15 |
| NervGen Pharma | 10 |
CGEN News
- 12 days ago - Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress - PRNewsWire
- 15 days ago - Compugen Transcript: Fireside chat - Transcripts
- 19 days ago - Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 - PRNewsWire
- 22 days ago - Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development - PRNewsWire
- 5 weeks ago - Compugen price target lowered to $5 from $13 at Leerink - TheFly
- 6 weeks ago - Compugen Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 6 weeks ago - Compugen files $400M mixed securities shelf - TheFly
- 6 weeks ago - Compugen Earnings Call Transcript: Q1 2026 - Transcripts